Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Arcus data the latest twist in the TIGIT story

BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo

By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma Intelligence
November 5, 2024 11:50 PM UTC

The TIGIT rollercoaster takes another turn, with overall survival data from a small study of Arcus’ domvanalimab that could swing sentiment in a positive direction, if slightly.

Arcus Biosciences Inc. (NYSE:RCUS) reported, ahead of a presentation at the Society for Immunotherapy of Cancer (SITC) conference this week, that domvanalimab plus PD-1 inhibitor zimberelimab reduced the risk of death by 36% when used as first-line therapy in patients with PD-L1-high non-small cell lung cancer (NSCLC) over zimberelimab alone...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Arcus Biosciences Inc.

Beam Therapeutics Inc.

Cogent Biosciences Inc.

Disc Medicine Inc.

Essa Pharma Inc.

Novo Nordisk A/S